Provention, Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Type 1 Diabetes

 

• Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D

• U.S. copromotion agreement leverages Sanofi's in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening

• Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval

• Investor Conference call at 8:30am ET Today

Provention Bio will discuss this business update via conference call today at 8:30 am ET. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.

https://finance.yahoo.com/news/provention-bio-combine-forces-sanofi-110000257.html